UroGen Pharma (URGN) Earnings Analysis
UroGen Pharma (URGN) next reports earnings on 2026-08-06, consensus EPS -0.28 USD. Last quarter (2026-03-02) it missed with EPS -0.54 USD vs -0.518 USD est (-4.2%). It has beaten estimates in 1/4 recent quarters (25%). Trailing P/E -15.29.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does URGN next report earnings?
| Next earnings date | 2026-08-06 |
|---|---|
| Consensus EPS estimate | -0.28 USD |
| Revenue estimate | 0.06B |
URGN earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-02 | -0.54 USD | -0.518 USD | -4.2% | Miss |
| 2025-11-06 | -0.69 USD | -0.72 USD | +4.2% | Beat |
| 2025-05-12 | -0.92 USD | -0.83 USD | -10.8% | Miss |
| 2025-03-10 | -0.8 USD | -0.69 USD | -15.9% | Miss |
Beat rate: 1/4 (25%) over reported quarters with consensus data.
URGN valuation and analyst view
| Trailing P/E | -15.29 |
|---|---|
| Trailing EPS | -2.6548 USD |
| Price / book | -16.99 |
| Dividend yield | 0.00% |
| Market cap | 2.09B |
| Analyst consensus | Buy (11 buy / 4 hold / 0 sell) |
| Avg price target | 45.25 USD |
Related research pages
Frequently asked questions
When is UroGen Pharma (URGN)'s next earnings date?
UroGen Pharma is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.28 USD and revenue estimate of 0.06B.
Did URGN beat earnings last quarter?
In its 2026-03-02 report, URGN posted EPS of -0.54 USD versus a -0.518 USD estimate — a miss of 4.2%.
What is URGN's earnings track record?
Over the last 4 reported quarters with consensus data, URGN beat estimates 1 times (25%).
What is URGN's current P/E ratio and EPS?
URGN trades at a trailing P/E of -15.29 on trailing EPS of -2.6547962947751893 USD.
What do analysts rate URGN?
Analyst consensus is "Buy" across 15 ratings (0 strong buy, 11 buy, 4 hold, 0 sell, 0 strong sell). Average 12-month price target: 45.25 USD.